支架跳跃法优化舒尼替尼的心脏毒性和甲状腺毒性。

Bhagyashri Chaudhari, Harun Patel, Snehal Thakar, Iqrar Ahmad, Deepali Bansode
{"title":"支架跳跃法优化舒尼替尼的心脏毒性和甲状腺毒性。","authors":"Bhagyashri Chaudhari,&nbsp;Harun Patel,&nbsp;Snehal Thakar,&nbsp;Iqrar Ahmad,&nbsp;Deepali Bansode","doi":"10.1007/s40203-022-00125-1","DOIUrl":null,"url":null,"abstract":"<p><p>Sunitinib is a potent anti-cancer scaffold that acts as a VEGFR-2 inhibitor. Although the scaffold exhibits potent anti-cancer activity, it is cardiotoxic and also induces hypothyroidism. The current research aims to optimize the Sunitinib for cardio-toxicity and thyro-toxicity by scaffold hopping approach using the admetSAR server. The server has optimized the physico-chemical properties of Sunitinib, which were contributing to the cardiotoxicity and thyro-toxicity. The library of the optimized compounds was further screened by the molecular docking studies and results were validated by the MD simulation and DFT analysis for VEGFR-2 inhibition. Compounds <b>163</b> and <b>432</b> exhibited the highest affinity to VEGFR-2 receptor with minimal cardiotoxicity and thyro-toxicity. These two compounds could be the starting point for the further discovery of angiogenic inhibitors.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40203-022-00125-1.</p>","PeriodicalId":13380,"journal":{"name":"In Silico Pharmacology","volume":"10 1","pages":"10"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250587/pdf/40203_2022_Article_125.pdf","citationCount":"24","resultStr":"{\"title\":\"Optimizing the Sunitinib for cardio-toxicity and thyro-toxicity by scaffold hopping approach.\",\"authors\":\"Bhagyashri Chaudhari,&nbsp;Harun Patel,&nbsp;Snehal Thakar,&nbsp;Iqrar Ahmad,&nbsp;Deepali Bansode\",\"doi\":\"10.1007/s40203-022-00125-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Sunitinib is a potent anti-cancer scaffold that acts as a VEGFR-2 inhibitor. Although the scaffold exhibits potent anti-cancer activity, it is cardiotoxic and also induces hypothyroidism. The current research aims to optimize the Sunitinib for cardio-toxicity and thyro-toxicity by scaffold hopping approach using the admetSAR server. The server has optimized the physico-chemical properties of Sunitinib, which were contributing to the cardiotoxicity and thyro-toxicity. The library of the optimized compounds was further screened by the molecular docking studies and results were validated by the MD simulation and DFT analysis for VEGFR-2 inhibition. Compounds <b>163</b> and <b>432</b> exhibited the highest affinity to VEGFR-2 receptor with minimal cardiotoxicity and thyro-toxicity. These two compounds could be the starting point for the further discovery of angiogenic inhibitors.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40203-022-00125-1.</p>\",\"PeriodicalId\":13380,\"journal\":{\"name\":\"In Silico Pharmacology\",\"volume\":\"10 1\",\"pages\":\"10\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250587/pdf/40203_2022_Article_125.pdf\",\"citationCount\":\"24\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"In Silico Pharmacology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s40203-022-00125-1\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"In Silico Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40203-022-00125-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 24

摘要

舒尼替尼是一种有效的抗癌支架,可作为VEGFR-2抑制剂。虽然支架显示出强大的抗癌活性,但它是心脏毒性的,也会引起甲状腺功能减退。目前的研究旨在利用admetSAR服务器通过支架跳跃方法优化舒尼替尼的心脏毒性和甲状腺毒性。该服务器优化了舒尼替尼的理化性质,这有助于心脏毒性和甲状腺毒性。通过分子对接研究进一步筛选优化的化合物文库,并通过MD模拟和DFT分析对VEGFR-2抑制效果进行验证。化合物163和432对VEGFR-2受体的亲和力最高,心脏毒性和甲状腺毒性最小。这两种化合物可能是进一步发现血管生成抑制剂的起点。补充信息:在线版本提供补充资料,网址为10.1007/s40203-022-00125-1。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Optimizing the Sunitinib for cardio-toxicity and thyro-toxicity by scaffold hopping approach.

Optimizing the Sunitinib for cardio-toxicity and thyro-toxicity by scaffold hopping approach.

Sunitinib is a potent anti-cancer scaffold that acts as a VEGFR-2 inhibitor. Although the scaffold exhibits potent anti-cancer activity, it is cardiotoxic and also induces hypothyroidism. The current research aims to optimize the Sunitinib for cardio-toxicity and thyro-toxicity by scaffold hopping approach using the admetSAR server. The server has optimized the physico-chemical properties of Sunitinib, which were contributing to the cardiotoxicity and thyro-toxicity. The library of the optimized compounds was further screened by the molecular docking studies and results were validated by the MD simulation and DFT analysis for VEGFR-2 inhibition. Compounds 163 and 432 exhibited the highest affinity to VEGFR-2 receptor with minimal cardiotoxicity and thyro-toxicity. These two compounds could be the starting point for the further discovery of angiogenic inhibitors.

Supplementary information: The online version contains supplementary material available at 10.1007/s40203-022-00125-1.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信